Pidotimod

Pidotimod is an orally active dipeptide immunostimulant with immunomodulatory properties on the adaptive and the innate immune responses. Pidotimod increases macrophage activity and humoral immune functions. Pidotimod can be used for the research of chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic idiopathic urticaria, et al[1][2].

Product Specifications

CAS Number

[121808-62-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Pidotimod.html

Concentration

10mM

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 25 mg/mL (ultrasonic)

Smiles

O=C([C@H]1N(C([C@H](CC2)NC2=O)=O)CSC1)O

Molecular Formula

C9H12N2O4S

Molecular Weight

244.27

Precautions

H302, H315, H319, H335

References & Citations

[1]Ashok Mahashur, et al. Pidotimod: In-depth review of current evidence. Lung India|[2]Ning Zhao, et al. Pidotimod: a review of its pharmacological features and clinical effectiveness in respiratory tract infections. Expert Rev Anti Infect Ther. 2019 Oct;17 (10) :803-818.